RealFeedApp beta

Eli Lilly buys Calytrix Bio for up to $1.5 billion

Eli Lilly agreed to pay up to $1.5 billion for Calytrix Bio, a biotech developing treatments for myeloproliferative neoplasms like myelofibrosis and essential thrombocythemia.

Field
business and funding
What they did
Eli Lilly acquired startup Calytrix Bio for up to $1.5 billion to gain access to its development of treatments for rare blood cancers.
Why it matters
The acquisition aims to expand the company's biotech portfolio, as the startup is developing therapies for conditions where the body overproduces red blood cells.
#lilly#calytrix#myeloproliferative neoplasms#myelofibrosis#biotech acquisition

Read the original →